小分子果胶是一种从柑橘橘络中提取的水溶性多糖，分子量仅为普通果胶的1/10，可直接被人体吸收并精准作用于癌细胞转移的关键靶点——半乳糖凝集素-3（Galectin-3）。

Feb. 18, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced additional results showing a ...

Galectin Therapeutics Inc. (NASDAQ:GALT), a pharmaceutical company focused on the development of treatments for fibrotic disease and cancer with a market capitalization of $76.57 million ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, unveiled a potential game-changer in the fight against Highly ...

Key Insights Galectin Therapeutics' significant individual investors ownership suggests that the key decisions ...

(RTTNews) - Galectin Therapeutics, Inc. (GALT), on Tuesday, announced additional data from the NAVIGATE trial showing a significant 68.1% reduction in the incidence of new varices in U.S. patients ...

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs ...

Detailed price information for Galectin Therapeutic (GALT-Q) from The Globe and Mail including charting and trades.

Galectin Therapeutics (NASDAQ:GALT) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents. This met the analyst estimate for EPS of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...